查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1445541

前列腺癌診斷市場評估：診斷技術、癌症類型、最終用戶和地區的機會和預測（2017-2031）

Prostate Cancer Diagnostics Market Assessment, By Diagnostic Technique, By Cancer Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 227 Pages | 商品交期: 3-5個工作天內

價格

全球攝護腺癌診斷市場規模將從2023年的63.1億美元成長到2031年的110.5億美元，2024-2031年預測期間內複合年增長率為7.26%，預計規模將持續成長。

全球前列腺癌診斷市場受到多種因素的影響。 這包括人工智慧等技術的進步、投資的增加、生物標記測試的主導地位、腺癌診斷工具以及對前列腺癌認識的提高。

技術進步

人工智慧和其他技術的進步正在對全球前列腺癌診斷市場的擴張產生重大影響。 人工智慧在診斷中的應用提高了前列腺癌的檢測效率和準確性。 透過檢查大型資料集，人工智慧演算法可以檢測人眼可能看不見的前列腺癌的特定跡象。 這使得人工智慧演算法能夠比傳統策略更快、更好地診斷癌症。 這種能力對於早期預後至關重要，因為它可以及時進行幹預。 人工智慧的使用正在徹底改變前列腺癌診斷領域，改善患者治療效果並加速公司發展。

增加投資

全球前列腺癌診斷市場由公司和組織資助，以鼓勵創造新想法。 需要獲得資金來開發檢測前列腺癌的新策略和加強研發工作的技術。 目前正在進行投資以支援新方法的開發和現有方法的改進，例如人工智慧驅動的診斷平台和先進的生物標記測試，這將在推動行業向前發展方面發揮關鍵作用。我是。 增加投資將刺激創新，並有助於擺脫過時的前列腺癌診斷技術。

生物標記測試的優點

前列腺癌診斷的急劇增加主要是由於對生物標記測試的需求不斷增加。 生物標記測試是最常用的技術，並且由於其許多優點而變得越來越受歡迎。 這些測試靈敏且特異，可以識別與前列腺癌相關的蛋白質和基因。 由於可以立即治療，因此甚至可以在症狀出現之前進行早期發現。 此外，生物標記測試可以提供有關癌症侵襲性和治療反應性的重要資訊，從而製定量身定制的治療策略。 需求的增加是由於前列腺癌檢測和治療的生物標記測試的效率和準確性。

腺癌診斷工具

由於引入了旨在檢測各種形式的前列腺癌（尤其是流行的腺癌）的創新設備，全球前列腺癌診斷市場正在經歷快速增長。 這些儀器利用最先進的技術，包括分子診斷和先進成像，來準確識別和表徵腺癌。 這是一個主要的臨床優勢。 有了有關腫瘤位置、大小和範圍的詳細信息，醫生可以製定高度針對性的治療計劃，以優化患者的治療效果。 這些專門的診斷工具滿足了早期準確檢測的迫切需求，被認為是成功治療前列腺癌的基石。

本報告調查了全球前列腺癌診斷市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素。我們編制分析、案例研究、競爭景觀、主要公司簡介等等。

目錄

第 1 章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章全球前列腺癌診斷市場展望

  • 市場規模/預測
  • 透過診斷技術
    • 影像檢查
    • 切片
    • 生物標記測試
    • 免疫組織化學
    • 其他
  • 依癌症類型
    • 鱗狀細胞癌
    • 小細胞前列腺癌
    • 腺癌
    • 移行細胞癌
    • 其他
  • 按最終用戶
    • 醫院
    • 癌症研究所
    • 診斷中心
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 各公司的市佔率

第 5 章全球前列腺癌診斷市場展望：按地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章市場映射

  • 透過診斷技術
  • 依癌症類型
  • 按最終用戶
  • 按地區

第 7 章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 生長抑制因素（問題、限制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第 10 章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家參與公司）
  • 專利分析（如果適用）

第 11 章價格分析

第 12 章案例研究

第 13 章主要公司展望

  • Roche Holdings AG
  • Siemens Healthineers AG
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific Inc.
  • Becton Dickinson and Company
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd.
  • Koninklijke Philips N.V.
  • Biocept Inc
  • Agilent Technologies, Inc.

第 14 章策略建議

第 15 章關於我們公司/免責聲明

Product Code: MX11090

Global prostate cancer diagnostics market is projected to witness a CAGR of 7.26% during the forecast period 2024-2031, growing from USD 6.31 billion in 2023 to USD 11.05 billion in 2031. The global prostate cancer diagnostics market is shaped by various factors. These include advancing technologies such as AI, an increase in investments, advantages of biomarker test offerings, tools for diagnosis of adenocarcinoma, and a rise in awareness of prostate cancer.

These factors are crucial for the growth and development of the market. Advancements in cutting-edge technologies, especially artificial intelligence (AI), play an important role in influencing the global prostate cancer diagnostics market. AI is responsible for the increasing speed and accuracy of diagnosis by analyzing large amounts of complex data for patterns that indicate prostate cancer.

Both public and private firms are heavily investing in the global prostate cancer diagnostics market. These investments are used for research and development purposes, which help in developing advanced solutions for the market. Often, public and private firms work together utilizing each other's strengths to spur innovation in the global prostate cancer diagnostics market. Hence, public private partnerships are often a successful model in the healthcare industry.

Another important aspect influencing the global prostate cancer diagnostics market is biomarker testing. By detecting a chemical in blood or tissue, biomarker testing provides important information that helps clinicians to make a diagnosis. Thus, due to the accuracy and reliability provided by biomarkers, they are considered important devices for early detection and monitoring of prostate cancer.

Significant developments have been made in the improvement of specialized instruments meant for the diagnosis of adenocarcinoma, the most common form of prostate cancer. By using these instruments, malignant cells in the prostate may be exactly identified and defined, taking into consideration extra-centered and successful remedy plans. It is a significant factor influencing the growth of global prostate cancer diagnostics market.

Consequently, there has been a tremendous impact from the increased expertise in prostate cancer. Higher screening quotes, early detection, and better remedy outcomes have resulted from elevated widespread public expertise and comprehension of the disorder. For instance, Astellas, a Japanese multinational pharmaceutical company, provided financing support for the Prostate Health Awareness and Screening Campaign (PHASC) in June 2023 with the support of MAP International. It is a multifaceted strategy aimed at increasing public knowledge of a malignancy that has been historically underrepresented in the Dominican Republic through the media.

Technological Advancements

The expansion of global prostate cancer diagnostics market is being significantly affected by advancing technologies specifically AI. The use of AI in diagnostic methods improves prostate cancer detection efficiency and accuracy. AI algorithms can detect certain signs of prostate cancer that may go unnoticed by the human eye by examining big datasets. It permits AI algorithms to diagnose cancer more quickly and appropriately than traditional strategies. The capability is crucial for early prognosis since it makes timely interventions that might save lives. As a result, using AI is causing a revolution inside the field of prostate cancer diagnostics, improving affected person outcomes and accelerating enterprise expansion.

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center were awarded a three-year, USD 3 million grant by the National Cancer Institute in December 2023 to help prevent needless treatments and their unfavorable side effects. The goal of this grant is to identify novel cancer biomarkers and develop AI that can detect and predict aggressive prostate cancer.

Increase in Investments

The global prostate cancer diagnostics market receives funding from businesses and organizations to encourage the creation of new ideas. Access to funding is necessary to enable the development of new strategies for the detection of prostate cancer and technologies to enhance research and development efforts. Investments are being made to help develop new methods and improve upon existing methods, such as AI-powered diagnostic platforms and sophisticated biomarker tests which play an important role in driving the industry forward. Increased investments spur innovation and help in getting rid of the age-old technologies for diagnosing prostate cancer.

On 13th February, Macmillan Cancer Support announced their investment of GBP 350,100 in Pi, Lucida Medical's new AI platform, to improve the accuracy and efficiency of prostate cancer tests.

Advantages that the Biomarker Test Offers

Prostate cancer diagnosis is increasing exponentially mainly due to the growing demand for biomarker testing. Biomarker tests are the most commonly used methods and are becoming increasingly popular due to their numerous advantages. As these tests are highly sensitive and specific, they can identify the proteins or genes associated with prostate cancer. It allows for an immediate response that allows for early detection of the condition, even before symptoms appear. In addition, biomarker testing may enable the development of tailored treatment strategies by providing important information about cancer aggressiveness and responsiveness to treatment. Increasing demand is due to the efficiency and accuracy of biomarker testing for the detection and treatment of prostate cancer, emphasizing its importance in the global prostate cancer diagnostics market.

In July 2023, Quest Diagnostics announced the introduction of AmeriPath, a new prostate cancer biomarker test in association with Envision Sciences, which is its subspecialty pathology division. Envision Sciences Pty Ltd. is creating a pipeline of blood and tissue biomarker-based cancer diagnostic and predictive assays.

Tools for Diagnosis of Adenocarcinoma

The global prostate cancer diagnostics market is experiencing a surge, driven by the introduction of innovative instruments designed to detect its diverse forms, particularly the prevalent adenocarcinoma. These instruments leverage cutting-edge technologies like molecular diagnostics and advanced imaging, offering precise identification and characterization of adenocarcinomas. It translates to a significant clinical advantage. Armed with detailed information on tumor location, size, and extent, physicians can formulate highly targeted treatment plans, optimizing patient outcomes. These specialized diagnostic tools address a critical need for early and accurate detection, considered as a cornerstone of successful prostate cancer management.

Consequently, the launch of these instruments represents a strategic market mover, catering to the burgeoning demand for sophisticated diagnostic solutions. The development benefits patients through improved clinical outcomes and propels the industry forward by addressing a crucial unmet need. The advancements signify a positive trajectory for the prostate cancer diagnostics market, paving the way for enhanced patient care and industry growth.

Prostate cancer may be diagnosed by pathologists using QAi Prostate, a sophisticated artificial intelligence (AI) technology that was unveiled in March 2023 by Singapore-based healthtech startup Qritive. QAi Prostate uses sophisticated machine learning (ML) algorithms to reliably identify regions of prostatic adenocarcinoma and classify benign and malignant tumor locations in biopsy tissue samples.

North America to Dominate the Market

North America stands as the leader in the global prostate cancer diagnostics market. The region is expected to dominate due to its advanced healthcare system and the concerning rates of disease in specific populations. The region boasts a sophisticated healthcare infrastructure that fosters exhilarating innovation. It translates to intensified research, development, and adoption of cutting-edge diagnostic technologies, propelling the market forward at a rapid pace. Powerful tools like molecular diagnostics and advanced imaging empower early detection and more precise diagnosis. Also, the need for these advancements resonates deeply in communities disproportionately affected by the disease. Native American and Black men face alarmingly high prostate cancer rates, highlighting the urgent need for effective diagnostic methods. In North Carolina, prostate cancer sits as the second-highest cause of male cancer deaths, further underlining the criticality of early identification.

An interactive web application was introduced in December 2023 by Carolina Demography and The UNC Men's Health Programme to eliminate prostate cancer inequities in North Carolina and increase public awareness of the disease.

Future Market Scenario

Introduction of new biomarkers such as 4Kscore, TMPRSS2-ERG fusion, and PCA3 to diagnose prostate cancer correctly and with improved efficiency to spur the global prostate cancer diagnostics market in the future.

The increasing number of cases of adenocarcinoma will drive the growth of the global prostate cancer diagnostics market.

Patients preferring more cost-effective and personalized treatment options in the global prostate cancer diagnostics market will force the healthcare industry to adapt to more faster and convenient methods of diagnosis.

With new startups entering the global prostate cancer diagnostics market, there will be an outburst of new technological interventions to diagnose prostate cancer.

Key Players Landscape and Outlook

The global prostate cancer diagnostics market is witnessing a significant shift towards strategic partnerships between startups and small businesses. The collaborative approach allows these entities to surmount financial and technological hurdles that might otherwise impede their independent progress. By pooling resources, knowledge, and cutting-edge technologies, these alliances can significantly accelerate research and development activities, leading to the emergence of innovative diagnostic tools and techniques. Such partnerships create a dynamic and competitive market environment, fostering a culture of continuous innovation. The diversity of ideas and expertise brought together by these partnerships results in a broader spectrum of diagnostic solutions.

Leading AI-powered biopharmaceutical company BPGbio, Inc. has partnered with Grupo Terralpe, Inc. in July 2023. The businesses will collaborate to market BPGbio's prostate cancer diagnostic test, pstateDx, in Mexico.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Prostate Cancer Diagnostics Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Diagnostic Technique
    • 4.2.1. Imaging Tests
      • 4.2.1.1. Ultrasound
      • 4.2.1.2. Positron Emission Tomography (PET) Scan
      • 4.2.1.3. Magnetic Resonance Imaging (MRI)
      • 4.2.1.4. Computerized Tomography (CT) Scan
      • 4.2.1.5. Bone Scan
    • 4.2.2. Biopsy
    • 4.2.3. Biomarker Tests
    • 4.2.4. Immunohistochemistry
    • 4.2.5. Others
  • 4.3. By Cancer Type
    • 4.3.1. Squamous Cell Carcinoma
    • 4.3.2. Small Cell Prostate Cancer
    • 4.3.3. Adenocarcinoma
    • 4.3.4. Transitional Cell Carcinoma
    • 4.3.5. Others
  • 4.4. By End-user
    • 4.4.1. Hospitals
    • 4.4.2. Cancer Research Institutes
    • 4.4.3. Diagnostic Centers
    • 4.4.4. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia-Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Prostate Cancer Diagnostics Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Diagnostic Technique
      • 5.1.2.1. Imaging Tests
      • 5.1.2.1.1. Ultrasound
      • 5.1.2.1.2. Positron Emission Tomography (PET) Scan
      • 5.1.2.1.3. Magnetic Resonance Imaging (MRI)
      • 5.1.2.1.4. Computerized Tomography (CT) Scan
      • 5.1.2.1.5. Bone Scan
      • 5.1.2.2. Biopsy
      • 5.1.2.3. Biomarker Tests
      • 5.1.2.4. Immunohistochemistry
      • 5.1.2.5. Others
    • 5.1.3. By Cancer Type
      • 5.1.3.1. Squamous Cell Carcinoma
      • 5.1.3.2. Small Cell Prostate Cancer
      • 5.1.3.3. Adenocarcinoma
      • 5.1.3.4. Transitional Cell Carcinoma
      • 5.1.3.5. Others
    • 5.1.4. By End-user
      • 5.1.4.1. Hospitals
      • 5.1.4.2. Cancer Research Institutes
      • 5.1.4.3. Diagnostic Centers
      • 5.1.4.4. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
      • 5.1.5.1.1. By Value
      • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Diagnostic Technique
      • 5.1.5.2.1. Imaging Tests
      • 5.1.5.2.1.1. Ultrasound
      • 5.1.5.2.1.2. Positron Emission Tomography (PET) Scan
      • 5.1.5.2.1.3. Magnetic Resonance Imaging (MRI)
      • 5.1.5.2.1.4. Computerized Tomography (CT) Scan
      • 5.1.5.2.1.5. Bone Scan
      • 5.1.5.2.2. Biopsy
      • 5.1.5.2.3. Biomarker Tests
      • 5.1.5.2.4. Immunohistochemistry
      • 5.1.5.2.5. Others
      • 5.1.5.3. By Cancer Type
      • 5.1.5.3.1. Squamous Cell Carcinoma
      • 5.1.5.3.2. Small Cell Prostate Cancer
      • 5.1.5.3.3. Adenocarcinoma
      • 5.1.5.3.4. Transitional Cell Carcinoma
      • 5.1.5.3.5. Others
      • 5.1.5.4. By End-user
      • 5.1.5.4.1. Hospitals
      • 5.1.5.4.2. Cancer Research Institutes
      • 5.1.5.4.3. Diagnostic Centers
      • 5.1.5.4.4. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Diagnostic Technique
  • 6.2. By Cancer Type
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Roche Holdings AG
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Siemens Healthineers AG
  • 13.3. Myriad Genetics, Inc.
  • 13.4. Thermo Fisher Scientific Inc.
  • 13.5. Becton Dickinson and Company
  • 13.6. AstraZeneca plc
  • 13.7. F. Hoffmann-La Roche Ltd.
  • 13.8. Koninklijke Philips N.V.
  • 13.9. Biocept Inc
  • 13.10. Agilent Technologies, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 3. Global Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 4. Global Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 5. Global Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Prostate Cancer Diagnostics Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 9. North America Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 10. North America Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 11. North America Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 15. United States Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 16. United States Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 17. United States Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 20. Canada Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 21. Canada Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 22. Canada Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 25. Mexico Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 26. Mexico Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 27. Mexico Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 30. Europe Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 31. Europe Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 32. Europe Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 36. Germany Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 37. Germany Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 38. Germany Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 41. France Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 42. France Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 43. France Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 46. Italy Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 47. Italy Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 48. Italy Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 51. United Kingdom Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 52. United Kingdom Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 53. United Kingdom Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 56. Russia Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 57. Russia Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 58. Russia Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 61. Netherlands Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 62. Netherlands Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 63. Netherlands Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 66. Spain Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 67. Spain Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 68. Spain Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 71. Turkey Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 72. Turkey Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 73. Turkey Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 76. Poland Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 77. Poland Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 78. Poland Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 81. South America Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 82. South America Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 83. South America Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 87. Brazil Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 88. Brazil Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 89. Brazil Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 92. Argentina Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 93. Argentina Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 94. Argentina Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 97. Asia-Pacific Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 98. Asia-Pacific Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 99. Asia-Pacific Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 101. India Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 103. India Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 104. India Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 105. India Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 108. China Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 109. China Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 110. China Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 113. Japan Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 114. Japan Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 115. Japan Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 118. Australia Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 119. Australia Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 120. Australia Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 123. Vietnam Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 124. Vietnam Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 125. Vietnam Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 128. South Korea Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 129. South Korea Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 130. South Korea Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 133. Indonesia Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 134. Indonesia Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 135. Indonesia Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 138. Philippines Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 139. Philippines Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 140. Philippines Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 143. Middle East & Africa Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 144. Middle East & Africa Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 145. Middle East & Africa Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 149. Saudi Arabia Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 150. Saudi Arabia Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 151. Saudi Arabia Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 154. UAE Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 155. UAE Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 156. UAE Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 159. South Africa Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 160. South Africa Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 161. South Africa Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Diagnostic Technique Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023